AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy

September 24, 2010

AMSTERDAM, September 24, 2010 /PRNewswire-FirstCall/ — Amsterdam
Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the
field of human gene therapy, announced today that the U.S. Food and Drug
Administration (FDA) has designated AMT-080, a gene therapy for Duchenne
muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee
for Orphan Medical Products of the European Medicines Agency granted AMT-080
orphan designation for the same indication in the European Union.

AMT has shown efficacy in studies of a preclinical model of DMD. These
proof of concept studies demonstrated that AMT’s technology resulted in
functional dystrophin synthesis in both the heart and skeletal muscles,
leading to the prevention of muscular dystrophy. These data are strengthened
by a study in which this gene therapy approach was shown to successfully
restore dystrophin activity in diseased human muscle cells obtained from
biopsies of DMD patients. A Phase I/II clinical trial is scheduled to start
by the end of 2012.

AMT has received an Innovation Credit of up to EUR 4 million from the
Dutch government to support the development of AMT’s gene therapy treatment
for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem,
an agency of the Dutch Ministry of Economic affairs.

“It is exceptional that we have been able to reveal the promise of this
therapy to the FDA in this early stage of the development. We believe our
proven adenoassociated viral vector technology used in all our gene therapy
products provides a distinct advantage. AMT has successfully conducted three
clinical trials with its lead product Glybera that employs this technology,
confirming that AAV-based delivery technology is safe and efficacious,” noted
Jörn Aldag, CEO of Amsterdam Molecular Therapeutics.

The FDA’s orphan drug designation is intended to encourage research and
development of new therapies for diseases that affect fewer than 200,000 U.S.
residents. As a designated orphan drug, AMT-080 is eligible for tax credits
based on its clinical development costs, as well as assistance from the FDA
in guiding the drug through the regulatory approval process. The designation
provides the opportunity for AMT-080 to obtain market exclusivity for seven
years from the drug’s marketing approval date.

About Duchenne Muscular Dystrophy

DMD is a severe disease characterized by progressive muscle degeneration.
It affects young children, almost exclusively boys, and leads to progressive
paralysis and death in young adulthood. The disease is caused by mutations in
the dystrophin gene, as a result of which the production of functional
dystrophin protein, an important structural component within muscle tissue,
is blocked. Currently, there is no treatment to prevent the fatal outcome of
this disease. DMD affects one in 3,500 males, making it one of the most
prevalent of muscular dystrophies.

About Amsterdam Molecular Therapeutics (AMT) Holding N.V.

AMT, founded in 1998 and based in Amsterdam, is a leader in the
development of human gene based therapies. Using AAV as the delivery vehicle
of choice for therapeutic genes, the company has been able to design and
validate what is probably the first stable and scalable AAV production
platform. This safe and efficacious proprietary platform offers a unique
manufacturing capability which can be applied to a large number of rare
(orphan) diseases that are caused by one faulty gene. Currently, AMT has a
product pipeline with several AAV-based gene therapy products in LPLD,
Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson’s Disease at
different stages of research or development.


Certain statements in this press release are “forward-looking statements”
including those that refer to management’s plans and expectations for future
operations, prospects and financial condition. Words such as “strategy,”
“expects,” “plans,” “anticipates,” “believes,” “will,” “continues,”
“estimates,” “intends,” “projects,” “goals,” “targets” and other words of
similar meaning are intended to identify such forward-looking statements.
Such statements are based on the current expectations of the management of
Amsterdam Molecular Therapeutics (AMT) Holding N.V. only. Undue reliance
should not be placed on these statements because, by their nature, they are
subject to known and unknown risks and can be affected by factors that are
beyond the control of AMT. Actual results could differ materially from
current expectations due to a number of factors and uncertainties affecting
AMT’s business, including, but not limited to, the timely commencement and
success of AMT’s clinical trials and research endeavors, delays in receiving
U.S. Food and Drug Administration or other regulatory approvals (i.e. EMA,
Health Canada), market acceptance of AMT’s products, effectiveness of AMT’s
marketing and sales efforts, development of competing therapies and/or
technologies, the terms of any future strategic alliances, the need for
additional capital, the inability to obtain, or meet, conditions imposed for
required governmental and regulatory approvals and consents. AMT expressly
disclaims any intent or obligation to update these forward-looking statements
except as required by law. For a more detailed description of the risk
factors and uncertainties affecting AMT, refer to the prospectus of AMT’s
initial public offering on June 20, 2007, and AMT’s public announcements made
from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V

Source: newswire

comments powered by Disqus